No Data
Bio-thera solutions (688177.SH): The company's bevacizumab has not yet started selling in the European Union and the USA.
Ge Longhui 21st November丨Bio-Thera Solutions (688177.SH) stated on the interactive platform that the company's Bevacizumab monoclonal antibody has not yet started sales in the European Union and USA; TOFIDENCE (Tuzumab monoclonal antibody) started sales in the USA in May this year, and the listing time in the European Union is yet to be determined. Other overseas markets have not yet been approved for listing, and the company will actively follow up to promote the relevant processes. The company recognizes revenue in accordance with accounting standards, and part of the 10 million milestone from Hikma is included in the revenue. For specific information on the breakdown of revenue, please refer to the company's disclosure in the "Bio-Thera Solutions 2024 Interim Report" in statutory media.
Bio-Thera Solutions Receives $10 Million Payment Related to Licensing Deal
bio-thera solutions has achieved some results in overseas authorization, with 10 million USD entering the account, which may alleviate cash / money market tightness.
After authorizing the injection of BAT2206 (Keytruda monoclonal antibody) to Jirui Medicine for one month, bio-thera solutions received a payment of 10 million US dollars from the other party, providing supplementary cash flow for rapid consumption; Due to intense competition in the domestic market and vast market space overseas, apart from bio-thera solutions, many pharmaceutical enterprises have completed overseas expansion this year.
Bio-Thera Solutions (688177.SH): received a one-time payment of $10 million from Jirui Pharmaceuticals.
Bio-Thera Solutions (688177.SH) announced on November 13 that on October 8, 2024, Bio-Thera signed an authorization, production, supply, and commercialization agreement with Gedeon Richter Plc. (referred to as "Gedeon Richter") for BAT2206 (ustekinumab) injection. The exclusive commercialization rights for the company's BAT2206 (ustekinumab) injection in the European Union, United Kingdom, Swiss Franc, Australia, and some other European countries' markets were granted to Gedeon Richter on a compensated license. The total amount of the down payment and milestone payment is up to 0.11 billion US dollars.
Bio-Thera Solutions, Ltd.'s (SHSE:688177) Last Week's 8.7% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Biotech 2024 Third Quarter Report
Bio-Thera Solutions, Ltd.'s (SHSE:688177) 26% Price Boost Is Out Of Tune With Revenues
